Life Sciences Archive » March, 2007

Life Sciences - March, 2007

120 articles

• California Pharmas Spar Over Chinese Licensing
• Abott Sues Teva, Sandoz, Ranbaxy Over Omnicef
• E.U. Targets Boehringer For Misuse Of Patent System
• Novartis Stops Drug Marketing Amid Safety Concerns
• Federal Circuit Backs Teva In Patent Challenge
• Clarity Needed For Scope Of Waiver As To Litigation Counsel
• Plaintiff Can't Cherry-Pick Court, Judges Rule
• Stryker Unit Wins Summary Judgment In Patent Case
• Merck's Fosamax Patent Reinstated In E.U.
• Schering Takes Aim At Glenmark Over Zetia
• Merck Wins Appeal To Prohibit Generic Eye Drug
• Pa. Health Insurers' Merger Stirs Antitrust Concerns
• Eckerd Prevails In Appeal Of FLSA Case
• Cooley Godward Kronish
• Jury Makes Diomed $12.5M Richer
• Firm Faces Trial Over Fen-Phen Settlement
• Tyco Files Suit Over Generic Sleep Aid
• FDA Moves To Improve In Wake Of Safety Scrutiny
• Settlements With Payments To Generics Increase: FTC
• Hemosol Granted Fourth Stay Extension
• FDA Banned From Approving More Generic Norvasc
• Illinois Jury Hands Merck A Win
• Critics Say Biologics Bill Doesn't Protect Innovators
• Merck KGaA Unit Files Patent Suit Against Sepracor
• Bayer, Novartis Settle MS Drug Dispute For $200M
• Pfizer Fills Shelves With Generic Norvasc
• Biovail Fires Kasowitz Benson In Document Debacle
• Italy Orders Merck To Grant Free Licenses
• Witnesses Voice Support For Biologic Pathway
• NYC Withdraws $3.75M Claim Against Curative
• BioSafe Creditors Bid For Chapter 11 Trustee
• Eisai Targeted Again Over Aciphex Patent
• FTC Taps Cephalon Again Over Provigil Deal
• Mylan Races To Launch Generic Norvasc
• Holland Snags Former Illinois AG Senior Counsel
• Scope Of Waiver Needs Clarification, Bright-Line Test
• Shire Ensnares Another Generic Co. Over Adderall
• Court Dismisses Patent Suit Against Stryker
• Appeals Court Deals Blow To Pfizer
• Amgen Asks High Court To Hear Landmark Case
• Pharmaceutical Holdings Admits Infringement In Deal
• Permanent Injunction Ends Topamax Patent Fight
• Sidley Austin Nets Antitrust Litigator
• Pfizer Whistleblower Challenges Claim Dismissal
• Oxfam Slams Abbott Over Thailand Standoff
• Barr Sued Over Plan For Schizophrenia Drug
• House Panel Shelves Debate On "Say And Pay" Bill
• McDermott Puts IP Group Under New Leadership
• Takeda Wins $16.8M In Fees For Misconduct
• FDA Proposes Tougher Guidelines For Advisers
• Cardinal Health Sued Over Tissue Implant Patents
• Interest Group Has No Standing In Medicare Suit
• Medtronic Wins Appeal Over Spinal Technology
• Pfizer Wins Celebrex Challenge
• Alexion's Soliris Blood Drug Draws New Patent Cases
• Court Upholds FDA Ban On Diet Pills
• High Court Seeks U.S. Opinion On Tamoxifen Case
• Milberg Weiss Class Action Bid Denied
• Medtronic Sues Cordis In New Stent Dispute
• Hospital Settles Medicare Allegations For $7.5M
• CalPERS Lists Cos. With Worst Corporate Governance
• D.C. Court Rebuffs Challenge To Pharmaceutical Statute
• Appeals Court Overturns Contraception Ruling
• DNA Manufacturer Sued For Patent Infringement
• Pepper Hamilton Snatches Attorney From DOJ
• Germany Tops International Trademark List
• Angiotech Triumphs In Stent Patent Appeal
• Glaxo Receives France's First Predatory Pricing Fine
• Wyeth Sues Fourth Drug Maker Over Generic Effexor
• Judge Orders Amerigroup To Cough Up $334M
• Zonare Lobs Counterclaims In Ultrasound Patent Spat
• Abbott Strikes Back In Thailand Drug Feud
• J&J Subpoenaed Over Topamax, Risperdal, Natrecor
• Lessons From The Genentech V. Insmed Trial
• Illumina Infringed Gene Detection Patents: Jury
• Judge Tosses Counterclaims In Eye Surgery Spat
• Braintree Labs Hit With Antitrust Suit Over MiraLax
• Judge Strikes Down Nellson Settlement
• Toronto Snapshot: Borden Ladner Gervais LLP
• Toronto Snapshot: Blake, Cassels & Graydon LLP
• Top Biotech IP Attorney Joins Holland & Knight
• FDA Issues New Anemia Drug Warnings
• FTC Follows Through On Express Scripts Query
• Jury Rules Vioxx Caused Heart Attack, Awards $47.5M
• HIPAA Violation May Form Basis for Lawsuit
• Pepper Hamilton Strengthens IP Group
• FDA Probes Off-Label Uses Of Drug-Coated Stents
• Jury To Decide Validity Of Iridex Patent
• Federal Circuit Delivers Blow To Abbott
• DOJ, SEC Reach Deal In Drug Maker's Insider-Trading
• Toronto Snapshot: Miller Thomson LLP
• Suit Comes Back To Haunt Medtronic
• Express Scripts Maintains Antitrust OK Within Reach
• Generic Pathway For Biologics Weighed At Hearing
• Express Scripts' Sweetened Bid Turns Sour
• D.C. Court Reinstates PBM Disclosure Laws
• Judge Allows $8.7M Ruling In Vioxx Case To Stand
• Antitrust Suit: Purdue Pharma Tricked PTO
• EEOC Smacks Walgreens With Race Bias Suit
• Spine Implant Suit Disappears After A Day
• Judge Lifts Injunction On Drug Maker
• Gobbledygook At The Supreme Court
• Genentech, Tercica, Insmed Settle Patent Suit
• Judge Declines To Overturn Vioxx Jury Verdict
• Solvay Loses False Advertising, Trademark Case
• Gore-Tex Maker Sued Over Surgical Material
• House Committee Probes Drug Makers
• Novartis Refuses To Yank Gleevec Lawsuit
• QLT, Novartis Settle Patent Dispute With Hospitals
• Roche Suit Over Diabetes Test Strips Crumbles
• Biovail Abandons Wellbutrin Litigation
• The EEOC's New Treatment Of Health Care Workers
• Sandoz Sued Over Schizophrenia Drug Patent
• Elan Targeted In Off-Label Marketing Probe
• Russia Launches Probe Of Glaxo Vaccine Trials
• U.K. Court Greenlights Pfizer Drug Supply Deal
• New Jersey Jury Splits In Vioxx Cases
• Third Wave Files Antitrust Claim Over HPV Test
• Software Maker Sues Boston Scientific For Piracy
• Express Scripts Seeks New Vote Delay